Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer

H. Miyata, M. Yamasaki, T. Makino, M. Tatsumi, Y. Miyazaki, T. Takahashi, Y. Kurokawa, S. Takiguchi, Masaki Mori, Y. Doki

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: [18F]fluorodeoxyglucose (FDG)-PET has been used to evaluate the response of primary tumours to neoadjuvant therapy for oesophageal cancer. The clinical significance of the number of PET-positive nodes before and after therapy has not been investigated previously. Methods: [18F]FDG-PET was performed before and 2–3 weeks after completion of neoadjuvant chemotherapy to identify the number of PET-positive nodes, and these numbers were assessed in relation to metabolic changes in the primary tumour. Results: Of 302 patients in total, 90 had no PET-positive nodes, 83 had one, 59 had two and 70 patients had three or more positive nodes before therapy. After treatment, the numbers were: none in 207 patients, one in 59, two in 20 and three or more in 16 patients. The number of PET-positive nodes after treatment was influenced by both the number of PET-positive nodes before therapy and the response to preoperative therapy, and correlated with the number of metastatic lymph nodes. Overall survival was longer in patients who had no PET-positive nodes after treatment than in those who had one or more. Multivariable analysis identified the numbers of PET-positive nodes before and after chemotherapy as independent prognostic factors, together with clinical response, tumour depth and lymph node involvement. Conclusion: The number of PET-positive nodes after treatment correlated with survival in patients with oesophageal cancer who underwent neoadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalBritish Journal of Surgery
Volume103
Issue number1
DOIs
Publication statusPublished - Jan 1 2016
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Esophageal Neoplasms
Lymph Nodes
Drug Therapy
Survival
Therapeutics
Neoplasms
Neoadjuvant Therapy

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. / Miyata, H.; Yamasaki, M.; Makino, T.; Tatsumi, M.; Miyazaki, Y.; Takahashi, T.; Kurokawa, Y.; Takiguchi, S.; Mori, Masaki; Doki, Y.

In: British Journal of Surgery, Vol. 103, No. 1, 01.01.2016, p. 97-104.

Research output: Contribution to journalArticle

Miyata, H. ; Yamasaki, M. ; Makino, T. ; Tatsumi, M. ; Miyazaki, Y. ; Takahashi, T. ; Kurokawa, Y. ; Takiguchi, S. ; Mori, Masaki ; Doki, Y. / Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. In: British Journal of Surgery. 2016 ; Vol. 103, No. 1. pp. 97-104.
@article{f7a95d453b89454b87e2306877775638,
title = "Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer",
abstract = "Background: [18F]fluorodeoxyglucose (FDG)-PET has been used to evaluate the response of primary tumours to neoadjuvant therapy for oesophageal cancer. The clinical significance of the number of PET-positive nodes before and after therapy has not been investigated previously. Methods: [18F]FDG-PET was performed before and 2–3 weeks after completion of neoadjuvant chemotherapy to identify the number of PET-positive nodes, and these numbers were assessed in relation to metabolic changes in the primary tumour. Results: Of 302 patients in total, 90 had no PET-positive nodes, 83 had one, 59 had two and 70 patients had three or more positive nodes before therapy. After treatment, the numbers were: none in 207 patients, one in 59, two in 20 and three or more in 16 patients. The number of PET-positive nodes after treatment was influenced by both the number of PET-positive nodes before therapy and the response to preoperative therapy, and correlated with the number of metastatic lymph nodes. Overall survival was longer in patients who had no PET-positive nodes after treatment than in those who had one or more. Multivariable analysis identified the numbers of PET-positive nodes before and after chemotherapy as independent prognostic factors, together with clinical response, tumour depth and lymph node involvement. Conclusion: The number of PET-positive nodes after treatment correlated with survival in patients with oesophageal cancer who underwent neoadjuvant chemotherapy.",
author = "H. Miyata and M. Yamasaki and T. Makino and M. Tatsumi and Y. Miyazaki and T. Takahashi and Y. Kurokawa and S. Takiguchi and Masaki Mori and Y. Doki",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/bjs.9965",
language = "English",
volume = "103",
pages = "97--104",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer

AU - Miyata, H.

AU - Yamasaki, M.

AU - Makino, T.

AU - Tatsumi, M.

AU - Miyazaki, Y.

AU - Takahashi, T.

AU - Kurokawa, Y.

AU - Takiguchi, S.

AU - Mori, Masaki

AU - Doki, Y.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: [18F]fluorodeoxyglucose (FDG)-PET has been used to evaluate the response of primary tumours to neoadjuvant therapy for oesophageal cancer. The clinical significance of the number of PET-positive nodes before and after therapy has not been investigated previously. Methods: [18F]FDG-PET was performed before and 2–3 weeks after completion of neoadjuvant chemotherapy to identify the number of PET-positive nodes, and these numbers were assessed in relation to metabolic changes in the primary tumour. Results: Of 302 patients in total, 90 had no PET-positive nodes, 83 had one, 59 had two and 70 patients had three or more positive nodes before therapy. After treatment, the numbers were: none in 207 patients, one in 59, two in 20 and three or more in 16 patients. The number of PET-positive nodes after treatment was influenced by both the number of PET-positive nodes before therapy and the response to preoperative therapy, and correlated with the number of metastatic lymph nodes. Overall survival was longer in patients who had no PET-positive nodes after treatment than in those who had one or more. Multivariable analysis identified the numbers of PET-positive nodes before and after chemotherapy as independent prognostic factors, together with clinical response, tumour depth and lymph node involvement. Conclusion: The number of PET-positive nodes after treatment correlated with survival in patients with oesophageal cancer who underwent neoadjuvant chemotherapy.

AB - Background: [18F]fluorodeoxyglucose (FDG)-PET has been used to evaluate the response of primary tumours to neoadjuvant therapy for oesophageal cancer. The clinical significance of the number of PET-positive nodes before and after therapy has not been investigated previously. Methods: [18F]FDG-PET was performed before and 2–3 weeks after completion of neoadjuvant chemotherapy to identify the number of PET-positive nodes, and these numbers were assessed in relation to metabolic changes in the primary tumour. Results: Of 302 patients in total, 90 had no PET-positive nodes, 83 had one, 59 had two and 70 patients had three or more positive nodes before therapy. After treatment, the numbers were: none in 207 patients, one in 59, two in 20 and three or more in 16 patients. The number of PET-positive nodes after treatment was influenced by both the number of PET-positive nodes before therapy and the response to preoperative therapy, and correlated with the number of metastatic lymph nodes. Overall survival was longer in patients who had no PET-positive nodes after treatment than in those who had one or more. Multivariable analysis identified the numbers of PET-positive nodes before and after chemotherapy as independent prognostic factors, together with clinical response, tumour depth and lymph node involvement. Conclusion: The number of PET-positive nodes after treatment correlated with survival in patients with oesophageal cancer who underwent neoadjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85006410553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006410553&partnerID=8YFLogxK

U2 - 10.1002/bjs.9965

DO - 10.1002/bjs.9965

M3 - Article

VL - 103

SP - 97

EP - 104

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 1

ER -